Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic inflammation and immunologic-based constraints in malignant disease.

Literature DB >> 21995576

Chronic inflammation and immunologic-based constraints in malignant disease.

Abstract

Acute inflammatory reactions benefit the host by supporting the effective clearance of pathogens and fostering wound healing, in addition to other self-preservative processes. However, when the inflammatory program is not resolved, becoming chronic in nature, it creates an environment conducive to cancer development and progression. Therefore, minimizing exposure to risk factors that contribute to chronic inflammation and reconditioning the host towards a state of (at least locoregional) acute inflammation would meaningfully impact cancer incidence and its treatment, respectively. Regarding cancer therapy, combinational treatments that both disrupt chronic inflammation and install specific adaptive type I immunity are predicted to enhance quality of life and extend the overall survival of patients.

Entities: Chemical Disease Gene Species

Mesh：

Year: 2011 PMID： 21995576 PMCID： PMC3225121 DOI： 10.2217/imt.11.113

Source DB: PubMed Journal: Immunotherapy ISSN： 1750-743X Impact factor: 4.196

73 in total

Review 1. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors: Subhra K Biswas; Alberto Mantovani
Journal: Nat Immunol Date: 2010-09-20 Impact factor: 25.606

Review 2. A perspective on cancer cell metastasis.

Authors: Christine L Chaffer; Robert A Weinberg
Journal: Science Date: 2011-03-25 Impact factor: 47.728

Review 3. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

Authors: Markus F Neurath; Susetta Finotto
Journal: Cytokine Growth Factor Rev Date: 2011-03-05 Impact factor: 7.638

Review 4. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.

Authors: Alfredo Carrato Mena; Enrique Grande Pulido; Carmen Guillén-Ponce
Journal: Anticancer Drugs Date: 2010-01 Impact factor: 2.248

5. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.

Authors: Hajime Shibuya; Hisae Iinuma; Ryu Shimada; Atsushi Horiuchi; Toshiaki Watanabe
Journal: Oncology Date: 2011-03-17 Impact factor: 2.935

Review 6. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors: Je-In Youn; Dmitry I Gabrilovich
Journal: Eur J Immunol Date: 2010-11 Impact factor: 5.532

Review 7. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors: Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal: Cancer Chemother Pharmacol Date: 2009-12-05 Impact factor: 3.333

Review 8. Complexity of tumor vasculature in clear cell renal cell carcinoma.

Authors: Chao-Nan Qian; Dan Huang; Bill Wondergem; Bin Tean Teh
Journal: Cancer Date: 2009-05-15 Impact factor: 6.860

9. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Authors: Qingyu Zhou; Ping Guo; James M Gallo
Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531

10. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Authors: Dan Huang; Yan Ding; Yan Li; Wang-Mei Luo; Zhong-Fa Zhang; John Snider; Kristin Vandenbeldt; Chao-Nan Qian; Bin Tean Teh
Journal: Cancer Res Date: 2010-01-26 Impact factor: 12.701

23 in total

1. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

Authors: Aleksandra M Urbanska; Emmanouil D Karagiannis; Gonzalo Guajardo; Robert S Langer; Daniel G Anderson
Journal: Biomaterials Date: 2012-04-01 Impact factor: 12.479

2. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors: Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal: Clin Cancer Res Date: 2017-02-13 Impact factor: 12.531

3. Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis.

Authors: Randall E Ryan; Bryan Martin; Liliana Mellor; Reed B Jacob; Ken Tawara; Owen M McDougal; Julia Thom Oxford; Cheryl L Jorcyk
Journal: Cytokine Date: 2015-01-23 Impact factor: 3.861

4. Applying the uncertainty principle to immunology.

Authors: Ena Wang; Francesco M Marincola
Journal: Immunotherapy Date: 2011-10 Impact factor: 4.196

Review 5. Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders.

Authors: Sara K Story; Michael K Schowalter; Larisa J Geskin
Journal: Oncologist Date: 2013-02-21

6. Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia.

Authors: Takashi Iwata; Takuma Fujii; Kenji Morii; Miyuki Saito; Juri Sugiyama; Hiroshi Nishio; Tohru Morisada; Kyoko Tanaka; Tomonori Yaguchi; Yutaka Kawakami; Daisuke Aoki
Journal: Int J Clin Oncol Date: 2014-03-01 Impact factor: 3.402

7. Betulinic acid regulates generation of neuroinflammatory mediators responsible for tissue destruction in multiple sclerosis in vitro.

Authors: Jana Blaževski; Filip Petković; Miljana Momčilović; Reinhard Paschke; Goran N Kaluđerović; Marija Mostarica Stojković; Djordje Miljković
Journal: Acta Pharmacol Sin Date: 2013-02-04 Impact factor: 6.150